Survodutide (10mg Vials)

Survodutide is an investigational peptide-based medication being studied for its potential effects on body weight, metabolic health, and liver disease. It is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 (GLP-1) receptor, designed to influence pathways involved in appetite regulation, energy metabolism, and glucose control. Clinical research has investigated survodutide in areas including obesity, overweight, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Studies have reported effects on body weight and metabolic and liver-related measures, although research is ongoing.